Please assess the completion status of the following clinical trial:

Trial Title: Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 80~* If female, postmenopausal or surgically sterilized~* Liver metastases from colorectal carcinoma scheduled for a CT/MRI-guided single-fraction interstitial HDR brachytherapy~* Non-cirrhotic liver~* Life expectancy longer than 6 months~* willing and able to undergo all study procedures~* Having voluntarily provided written and fully informed consent~Exclusion Criteria:~* Women who are pregnant, lactating or who are of childbearing potential~* Liver cirrhosis~* Hepatitis B~* Hepatitis C~* Patients being clinically unstable~* Uncooperative, in the investigator's opinion~* Having been previously enrolled in this study~* Participating in another therapy-modulating clinical trial~* Contraindication for MRI~* Contraindication or hypersensitivity to one or more components of Gd-EOB-DTPA, Enoxaparin, Ursodeoxycholic acid and/or Pentoxifylline~* Any prior irradiation therapy of the liver~* Close affiliation with the investigational site; e.g. a close relative of the investigator~* Severe coronary artery disease~* Autoimmune diseases~* Acute bacterial endocarditis~* Active major bleedings and high rish of uncontrolled haemorrhage~* Patients with severe or moderate renal impairment (GFR below 60 mL/min/1.73 m2 according to the MDRD or Cockroft-Gault formula, calculated from a creatinine value obtained within 1 week before each planned Primovist-enhanced MR examination)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Medication group with patients receiving the study medication according to the study protocol for 8 weeks after HDR brachytherapy.
- Group B (Type: NO_INTERVENTION): Comparison group with patients receiving the standard therapy of HDR brachytherapy without the study specific medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).